Compounded vs branded GLP-1: what clinic operators need to know
June 2026 · 7 min read
Compounded GLP-1s filled a gap during shortages — but the regulatory picture is narrower and more state-specific than the marketing suggests. Here is what a clinic operator should understand before offering them.
Branded GLP-1s — the FDA-approved products from their manufacturers — sit alongside compounded versions prepared by pharmacies. The two are not interchangeable in the eyes of regulators, and the rules shift by state and over time.
Why compounding exists
Compounding pharmacies (503A and 503B facilities) can prepare medications to meet patient needs, and demand surged during branded-product shortages. As shortages resolve, the legal basis for compounding a given molecule can narrow — which makes "is this still permitted?" a question to revisit, not answer once.
What operators should weigh
- Regulatory exposure — compounded permissibility is narrower and changes with shortage status.
- State notice requirements — some states mandate specific disclosure language to the patient.
- Sourcing and quality — the credentialing and track record of the compounding pharmacy.
- Patient communication — being clear about what the patient is receiving and why.
None of this is a reason to avoid the category outright — many programs offer both responsibly. It is a reason to build the guardrails: route by state, surface the required notices, and keep counsel in the loop as the rules move.
Route prescriptions by state, automatically
Plexus encodes per-state rules and required notices so the right guardrails fire without manual lookup.
This article is for general information only and is not legal advice. Telehealth and prescribing rules vary by state and change over time — confirm requirements with healthcare counsel before acting.